Although acquired ALK mutations remain an important resistance mechanism to ALK inhibitors currently guiding therapeutic decisions, heterogeneous ALK-independent signaling and non-mutation-driven pathways may equally influence cancer progression and treatment resistance. The gene discussed is ALK; the disease is cancer.